Jawahar L. Mehta profile photo

Jawahar L. Mehta

High Impact

Distingusihed Professor

Last publication 2025 Last refreshed 2026-05-16

faculty

Internal Med, College of Medicine

90 h-index 651 pubs 38,536 cited

Biography and Research Information

OverviewAI-generated summary

Jawahar L. Mehta, Distinguished Professor in Internal Medicine at the University of Arkansas for Medical Sciences, leads a research group that investigates cardiovascular diseases and their relationship with infectious diseases, including COVID-19. His work has examined various aspects of cardiovascular health, such as the role of NF-κB as a therapeutic target and the impact of loneliness and social isolation on cardiovascular outcomes. He has also focused on the implications of COVID-19, including meta-analyses on the efficacy of aspirin and colchicine for mortality and mechanical ventilation, and the analysis of cerebral venous sinus thrombosis following vaccination. Additionally, his research has touched upon HDL cholesterol levels and susceptibility to COVID-19, as well as concerns regarding myocarditis and pericarditis in adolescents following COVID-19 vaccination.

With a career marked by extensive publication, Mehta holds an h-index of 33 and has accrued over 6,749 citations across 144 publications. He is recognized as a highly cited researcher. His collaborations within the University of Arkansas for Medical Sciences include joint publications with Nishank Jain, Subhi J. Al’Aref, Srinivas Ayyadevara, and J. Curran Henson. His recent work also includes updates on new therapies for patients with chronic kidney disease (CKD).

Metrics

  • h-index: 90
  • Publications: 651
  • Citations: 38,536

Selected Publications

  • Disulfidptosis: A novel cell death mechanism with pathological significance and therapeutic potential in diseases (2026)
  • Knowledge gaps in revascularization strategies in the setting of type II myocardial infarction: A common clinical dilemma in contemporary practices (2026)
  • Functional Biochemistry of Iron and Its Cardiopulmonary Impact (2026)
  • Remodelling-derived pre-β1 and remnant HDL particles: a snapshot of reverse cholesterol transport dynamics and efficiency (2025)
  • Molecular Insights into Ischemia–Reperfusion Injury in Coronary Artery Disease: Mechanisms and Therapeutic Implications: A Comprehensive Review (2025)
    11 citations DOI OpenAlex
  • Addressing myocardial infarction in South-Asian populations: risk factors and machine learning approaches (2025)
    3 citations DOI OpenAlex
  • The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism (2025)
    3 citations DOI OpenAlex
  • Reply (2024)
    1 citation DOI OpenAlex
  • Applications of ChatGPT in Heart Failure Prevention, Diagnosis, Management, and Research: A Narrative Review (2024)
    8 citations DOI OpenAlex
  • Positive Implications of Introducing Mindfulness Techniques as a Platform for Preoperative Stress Reduction to Improve Patient Outcomes Postpercutaneous Coronary Intervention (2024)
  • ‘Exerkines’: A Comprehensive Term for the Factors Produced in Response to Exercise (2024)
    18 citations DOI OpenAlex
  • COVID-19 in the Initiation and Progression of Atherosclerosis (2024)
    22 citations DOI OpenAlex
  • Direct Impact of PCSK9 on SMC Senescence and Apoptosis: A New Focus in Cardiovascular Diseases (2024)
    4 citations DOI OpenAlex
  • Myosin light chain phosphatase is a downstream target of Rho-kinase in endothelin-1-induced transactivation of the TGF-β receptor (2024)
    2 citations DOI OpenAlex
  • The Interplay of Thiamine and Cardiovascular Diseases (2024)
    2 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

  • Anti-myeloma efficacy of FAP inhibitor in ex vivo and in vivo systems for primary myeloma Vantia Therapeutics Ltd. Principal Investigator
  • Structure based drug design for atherosclerosis targeted at LOX-1, a receptor for oxidized low-density lipoprotein American Heart Association (SouthWest Affiliate) Co-Investigator
  • Regulation of LOX-1 Expression by Pioglitazone Takeda Principal Investigator
  • TOPCAT: Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone AnTagonist NIH/Nat. Heart, Lung & Blood Institute - Pass Through: New England Research Insts., Inc. Principal Investigator
  • TOPCAT: Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone AnTagonist NIH/Nat. Heart, Lung & Blood Institute - Pass Through: New England Research Insts., Inc. Principal Investigator

Collaboration Network

242 Collaborators 67 Institutions 10 Countries

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics